Skip to main content

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Completed · Phase 3 · NCT05929066

Conditions: Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea

At a glance

Research payments reported, 2025
$14.9M
U.S. investigators named
49
Sites paid
48
Planned or actual enrollment
2,335

About the trial

Sponsor
Eli Lilly and Company
Tested
Retatrutide (drug), Placebo (drug)
Dates
Started 2023-07-10; completion 2026-04-30
Results posted
Not yet

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.

From ClinicalTrials.gov, last updated 2026-08-21. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $14.9M in research payments for this study in 2025 (123 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Great Lakes Research Group Inc $1.6M
  • North Georgia Clinical Research $1.4M
  • Northwest Clinical Research Center $1.1M
  • Artemis Headlands LLC $671,754
  • Studymetrix Research LLC $662,077
  • Medvadis Research Corp LLC $613,689
  • Suncoast Research $598,627
  • Futuresearch Trials of Neurology LP $593,938
  • Tribe Clinical Research LLC $518,976
  • Teradan Clinical Trials LLC $474,991
  • Northwestern University $421,152
  • Juno Research LLC $393,136
  • Palm Research Center Inc $366,100
  • Arizona Research Center $364,146
  • Clinvest Headlands LLC $352,839
  • Rochester Clinical Research Inc $318,226
  • Wrightsville Family Practice $315,575
  • Ponce School of Medicine $287,520
  • New Horizon Research Center $278,851
  • Yale University $276,696
  • Altoona Center for Clinical Research PC $269,430
  • Vanderbilt University Medical Center, TN $266,492
  • Dr Dennis M Lacey $255,935
  • Compass Point Research Inc $255,357
  • Cotton Oneil Msd of Stormont Vail Healthcare $254,947
  • David Fitzpatrick MD DBA E West Med Rsrch $245,838
  • Lillestol Research LLC $234,985
  • Clinical Neuroscience Solutions DBA Cns Hlthcare $205,256
  • Rainier Clinical Research Center $190,026
  • Chase Medical Research LLC $171,056
  • Medical Investigations Inc $159,228
  • Progressive Medical Concepts LLC $138,689
  • Neuro PAin Medical Center Inc $133,050
  • Carteret Medical Group LLC $130,750
  • Regents of the University of Colorado $120,785
  • Advanced Research Inc $119,932
  • Prairie Education and Research Coop $81,203
  • Future Search Trials of Dallas LP $6,293
  • Cleveland Clinic, OH $2,246
  • Clinvest Research LLC $1,101
  • $1,038
  • Great Lakes Medical Research LLC $843
  • Suncoast Clinical Research $788
  • Clinical Research Advantage $660
  • Advanced Research Institute $475
  • University of Colorado Hospital Authority, CO $405
  • Mountain View Clinical Research Inc $373
  • Rainier Clinical Research Center Inc $165
  • Vanderbilt University Medical Center $9

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.